Results 281 to 290 of about 224,855 (298)

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events

Journal of the American College of Cardiology, 2019
Michael Szarek, Harvey D White, Gregory G Schwartz   +2 more
exaly  

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

European Heart Journal, 2016
Patrick M Moriarty, Klaus G Parhofer, Vinaya Simha   +2 more
exaly  

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

European Heart Journal, 2016
Helen Colhoun, Henry N Ginsberg, Jennifer G Robinson   +2 more
exaly  

Odyssey

2004
openaire   +1 more source

Seasonal and static gravity field of Mars from MGS, Mars Odyssey and MRO radio science

Icarus, 2016
Antonio Genova, Sander Goossens, Frank G Lemoine   +2 more
exaly  

Odyssey

Scientific American, 1987
openaire   +1 more source

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

Diabetes, Obesity and Metabolism, 2018
Kausik K Ray, Lawrence A Leiter, Dirk Müller-Wieland   +2 more
exaly  

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)

American Journal of Cardiology, 2017
Daniel Gaudet, Jennifer G Robinson, Jay M Edelberg   +2 more
exaly  

Odyssey

1980
openaire   +1 more source

Odyssey

Critical Quarterly, 2002
openaire   +1 more source